Curi RMB Capital LLC Sells 22,276 Shares of Zoetis Inc. (NYSE:ZTS)

Curi RMB Capital LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 19.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 92,635 shares of the company's stock after selling 22,276 shares during the quarter. Curi RMB Capital LLC's holdings in Zoetis were worth $15,093,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. increased its position in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the fourth quarter worth approximately $44,000. Asset Planning Inc acquired a new position in shares of Zoetis in the 4th quarter valued at $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Zoetis during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ZTS shares. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $214.40.

Zoetis Stock Performance

Shares of ZTS traded up $1.25 on Thursday, reaching $152.16. 1,087,369 shares of the stock traded hands, compared to its average volume of 2,516,824. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock's 50-day moving average price is $159.06 and its 200-day moving average price is $169.10. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm has a market cap of $67.89 billion, a price-to-earnings ratio of 27.78, a P/E/G ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.